Celsion Co. (NASDAQ:CLSN) has earned an average recommendation of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $14.50.
A number of equities research analysts have recently weighed in on CLSN shares. Maxim Group upgraded Celsion from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a report on Wednesday, October 4th. Zacks Investment Research downgraded Celsion from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. ValuEngine downgraded Celsion from a “sell” rating to a “strong sell” rating in a report on Wednesday, November 15th. Finally, Oppenheimer started coverage on Celsion in a report on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 price target for the company.
Shares of Celsion (NASDAQ:CLSN) traded down $0.04 during midday trading on Wednesday, hitting $2.75. The stock had a trading volume of 336,256 shares, compared to its average volume of 575,982. Celsion has a 1-year low of $1.24 and a 1-year high of $8.75. The company has a market cap of $44.81, a P/E ratio of -0.47 and a beta of 1.23.
An institutional investor recently bought a new position in Celsion stock. Sabby Management LLC acquired a new position in shares of Celsion Co. (NASDAQ:CLSN) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned about 1.30% of Celsion at the end of the most recent reporting period. 3.97% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/05/brokerages-set-celsion-co-clsn-price-target-at-14-50.html.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.